These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19996587)

  • 1. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
    Martarelli D; Pompei P; Mazzoni G
    Chemotherapy; 2009; 55(6):425-32. PubMed ID: 19996587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S; Ohnishi Y; Kakudo K
    Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
    Tang XH; Lu MS; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant.
    Rivetti S; Lauriola M; Voltattorni M; Bianchini M; Martini D; Ceccarelli C; Palmieri A; Mattei G; Franchi M; Ugolini G; Rosati G; Montroni I; Taffurelli M; Solmi R
    Int J Immunopathol Pharmacol; 2011; 24(3):639-49. PubMed ID: 21978696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice.
    Martarelli D; Pompei P; Baldi C; Mazzoni G
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):809-17. PubMed ID: 17581752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
    Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRM197 in Combination With shRNA Interference of VCAM-1 Displays Enhanced Inhibitory Effects on Human Glioblastoma Cells.
    Hu Y; Lin X; Wang P; Xue YX; Li Z; Liu LB; Yu B; Feng TD; Liu YH
    J Cell Physiol; 2015 Aug; 230(8):1713-28. PubMed ID: 25201410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity.
    Kageyama T; Ohishi M; Miyamoto S; Mizushima H; Iwamoto R; Mekada E
    J Biochem; 2007 Jul; 142(1):95-104. PubMed ID: 17525101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
    Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
    Anticancer Res; 2010 Aug; 30(8):3143-9. PubMed ID: 20871033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
    Tang XH; Li M; Deng S; Lu MS
    Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
    Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
    Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
    Wang T; Subramanian C; Blagg BSJ; Cohen MS
    Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
    Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
    Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humanized gene replacement in mice reveals the contribution of cancer stroma-derived HB-EGF to tumor growth.
    Ichise T; Adachi S; Ohishi M; Ikawa M; Okabe M; Iwamoto R; Mekada E
    Cell Struct Funct; 2010; 35(1):3-13. PubMed ID: 20190463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of diphtheria toxin R domain mutants with enhanced inhibitory activity against HB-EGF.
    Suzuki K; Mizushima H; Abe H; Iwamoto R; Nakamura H; Mekada E
    J Biochem; 2015 May; 157(5):331-43. PubMed ID: 25432160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance.
    Wang F; Liu R; Lee SW; Sloss CM; Couget J; Cusack JC
    Oncogene; 2007 Mar; 26(14):2006-16. PubMed ID: 17001310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
    Nam SO; Yotsumoto F; Miyata K; Suzaki Y; Yagi H; Odawara T; Manabe S; Ishikawa T; Kuroki M; Mekada E; Miyamoto S
    Anticancer Res; 2014 Aug; 34(8):4615-20. PubMed ID: 25075108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.